197 related articles for article (PubMed ID: 24254975)
1. Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease.
Boronat M; García-Cantón C; López-Ríos L; Quevedo V; Lorenzo DL; Batista F; Riaño M; Nóvoa FJ
Diab Vasc Dis Res; 2014 Jan; 11(1):53-9. PubMed ID: 24254975
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 inhibitors- A new age in lipid management?
Grant PJ
Diab Vasc Dis Res; 2017 May; 14(3):171. PubMed ID: 28467196
[No Abstract] [Full Text] [Related]
3. Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Diabetes Obes Metab; 2016 Apr; 18(4):384-91. PubMed ID: 26679079
[TBL] [Abstract][Full Text] [Related]
4. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
Soran H; France MW; Kwok S; Dissanayake S; Charlton-Menys V; Younis NN; Durrington PN
Ann Clin Biochem; 2011 Nov; 48(Pt 6):566-71. PubMed ID: 22006975
[TBL] [Abstract][Full Text] [Related]
6. ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management.
de Nijs T; Sniderman A; de Graaf J
Crit Rev Clin Lab Sci; 2013 Nov; 50(6):163-71. PubMed ID: 24295059
[TBL] [Abstract][Full Text] [Related]
7. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.
Barkas F; Liberopoulos EN; Kostapanos MS; Liamis G; Tziallas D; Elisaf M
Angiology; 2015 Apr; 66(4):346-53. PubMed ID: 24830420
[TBL] [Abstract][Full Text] [Related]
8. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.
Bongard V; Dallongeville J; Arveiler D; Ruidavets JB; Amouyel P; Wagner A; Ferrières J
Arch Cardiovasc Dis; 2013 Feb; 106(2):93-102. PubMed ID: 23527913
[TBL] [Abstract][Full Text] [Related]
9. Comparison of therapeutic lipid target achievements among high-risk patients in Oman.
Al-Waili K; Al-Zakwani I; Al-Dughaishi T; Baneerje Y; Al-Sabti H; Al-Hashmi K; Farhan H; Habsi KA; Al-Hinai AT; Al-Rasadi K
Angiology; 2014 May; 65(5):430-5. PubMed ID: 23564019
[TBL] [Abstract][Full Text] [Related]
10. Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population.
Martinez-Hervas S; Real JT; Priego MA; Carratalá A; Sniderman AD; Carmena R; Ascaso JF
Int J Clin Pract; 2013 Jan; 67(1):81-8. PubMed ID: 23241052
[TBL] [Abstract][Full Text] [Related]
11. Management of non-high-density lipoprotein abnormalities.
Rosenson RS
Atherosclerosis; 2009 Dec; 207(2):328-35. PubMed ID: 19545870
[TBL] [Abstract][Full Text] [Related]
12. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
Udawat H; Goyal RK
Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
[TBL] [Abstract][Full Text] [Related]
14. Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices.
Corcillo A; Pivin E; Lalubin F; Pitteloud N; Burnier M; Zanchi A
Swiss Med Wkly; 2017; 147():w14459. PubMed ID: 28695552
[TBL] [Abstract][Full Text] [Related]
15. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
16. Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study.
Idris I; Tate H; Ahmad A; McCormack T
J Clin Lipidol; 2011; 5(4):316-23. PubMed ID: 21784378
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
[TBL] [Abstract][Full Text] [Related]
18. 2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: established knowledge and evidence gaps.
Paneni F
Diab Vasc Dis Res; 2014 Jan; 11(1):5-10. PubMed ID: 24254974
[No Abstract] [Full Text] [Related]
19. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
20. Diabetic dyslipidaemia: insights for optimizing patient management.
Vergès B
Curr Med Res Opin; 2005; 21 Suppl 1():S29-40. PubMed ID: 15811197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
